Peripheral Artery Disease: Treatments And Diagnostics Poised For Growth
The market for peripheral vascular interventions and diagnostics is poised for significant growth in the years ahead, driven by an aging population and the growing incidence of peripheral vascular disease, along with new technological developments such as drug-eluting balloons, which are inching closer to regulatory approval in the US.
You may also be interested in...
Drug-coated balloon (DCBs) catheters have become the latest weapon in the fight against peripheral artery disease in the US, although they have been in use in Europe for some time. While the number of procedures employing DCBs is still dwarfed by conventional angioplasty procedures, they are expected to grow at a much faster rate, fueling a market projected to reach $1 billion by 2020; meanwhile other procedures such as mechanical atherectomy are also expected to show significant growth.
The Medicare Evidence Development and Coverage Advisory Committee voted low to moderate support for the scientific evidence backing endovascular and other interventions to treat lower extremity peripheral artery disease.
The firm's Eluvia paclitaxel eluting stent, design for peripheral arteries, showed positive results in data from a small trial presented April 28 at the Charing Cross International Symposium in London.